TransCode Therapeutics Inc. RNAZ
1.69
0.04
2.42%
as of 25 Sep
- Market cap
- $27.9M
- P/E
- 0.0×
Follow RNAZ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 429.61% | (757.04%) | (872.24%) | (1,764.97%) |
+8 more TTM periods Free account |
|
| (58.12%) | (51.30%) | (42.75%) | (592.93%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(831.37%) | (372.93%) | (192.31%) | (1,506.55%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(23.62) | (23.33) | (28.33) | (17.42) | |
Free Cash Flow |
(22.61) | (21.40) | (19.54) | (14.52) | |
Capital Expenditures |
— | — | (0.02) | — | |
| Other line items | |||||
Cash ROIC |
117.06% | (151.90%) | (69.33%) | (340.71%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.49 | 0.49 | 0.54 | 0.53 | |
Depreciation/Fixed assets |
0.30 | 0.25 | 0.31 | 9.66 | |
Capex/Depreciation |
0.00 | 0.00 | (0.22) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(23.62) | (23.33) | (28.30) | (17.42) | |
Capex per Share |
0.00 | 0.00 | (0.04) | 0.00 | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates